RxDoctor Payments DataLook up a doctor →

George James, MD

Gastroenterology · Hermitage, TNNPI 1043217854

Payments from drug & device makers

$155,524in general payments, 2019–2025

Across 469 payments — averaging $331.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$77K
  • Boehringer Ingelheim$48K
  • Braintree Laboratories, Inc.$14K
  • Amgen$4K
  • UCB Biosciences Inc.$4K
  • AbbVie$2K
  • plus $8K from 41 others

What the payments were for

  • Food & beverage$8,990100%
  • Education$80%
  • Other$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$155,524 in reported general payments places this provider in the 90th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$87,673
Medicare patients
315
Services billed
1,732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab17$437,277
XifaxanRifaximin17$49,691
ZenpepLipase/Protease/Amylase12$26,755
LinzessLinaclotide33$23,871
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C33$4,590
Pantoprazole Sodium244$3,113
Mesalamine ErMesalamine15$2,975
Budesonide DrBudesonide14$2,521
Colestipol Hcl37$2,105
Omeprazole63$1,295
Colesevelam Hcl16$1,291
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates17$1,067
Entecavir14$838
Esomeprazole Magnesium20$646
Sucralfate25$599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$687$437,27717 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$1,048$54,28250 claims
Aimmune Therapeutics, Inc.Zenpep$78$26,75512 claims
AbbVieLinzess$1,622$23,87133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Hermitage

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →